COMBINATION THERAPY WITH STAVUDINE (D4T) AND DIDANOSINE (DDI) IN CHILDREN WITH ADVANCED HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION. • 1039

Objectives. To obtain information on the pharmacokinetic properties, tolerance, safety, and antiviral activity of combination therapy with d4T and ddI in children with advanced HIV infection.

Methods. Eight children (median age, 6.6 years; range, 2.8 to 12 years) with advanced HIV disease (median CD4+ count at baseline, 42 cells/uL; range, 8 to 553 cells/uL) were treated with d4T (2 mg/kg/day in two divided doses) and ddI (180 mg/m²/day in two divided doses) for 24 weeks. Seven children had a history of prior zidovudine therapy. All children had received d4T alone for periods of 19 to 33 months before addition of ddI. Children were assessed clinically and with laboratory studies at baseline, weekly through week four of combination therapy, and every four weeks thereafter.

Log in or create a free account to read this content

Gain free access to this article, as well as selected content from this journal and more on nature.com

Access through your institution

or

Sign in or create an account

Continue with Google

Continue with ORCiD